

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai - 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website : www.sunpharma.com
CIN : L24230GJ1993PLC019050



April 8, 2019

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.
NSE Code – SUNPHARMA

BSE Ltd,
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai - 400 001.
BSE Code– 524715

Dear Sirs,

Sub: Update on (a) Transition of India domestic formulations distribution to Sun Pharma's wholly owned subsidiary and (b) Completion of assignment from Atlas Global Trading to Sun Pharma's wholly owned subsidiary

We refer to our intimation dated 22nd January, 2019 to stock exchanges stating Sun Pharmaceutical Industry Limited's ("Sun Pharma") intent to (a) transition its distribution related to India domestic formulations business from Aditya Medisales Ltd ("AML"), the current distributor, to a wholly owned subsidiary of Sun Pharma and (b) unwinding of a transaction with Atlas Global Trading ("Atlas").

We wish to update that Sun Pharma Distributors Ltd (SPDL), a wholly-owned subsidiary of Sun Pharma Laboratories Limited has been incorporated and will w.e.f. April-2019, commence distributing Sun Pharma's formulation products in India, on the same terms as was with AML, in a phased manner upon receipt of requisite regulatory approvals. This phased transition is expected to be fully completed by Q1 of FY20.

The above-mentioned transition and consequential one-time reduction in sales and profit will impact Sun Pharma's financial results for the period ended 31st March 2019.

Further, in continuation of our intimation dated 22nd January, 2019, we wish to update that Atlas has completed assignment of its business rights and obligations including those arising from the supply contract with Sun Pharma to a wholly owned subsidiary of Sun Pharma. This has no material impact on the profit or loss for the year ended March 31, 2019.

This is for your information and records.

Yours faithfully,
For **Sun Pharmaceutical Industries Limited,**

Ashok I. Bhuta
Compliance Officer